Key facts
- This page summarizes Michael A. Mcmanus Jr.'s Form 4 filing for NOVAVAX INC (NVAX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2022, 20:48.
Michael A. Mcmanus Jr. - 16 Jun 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)
- Reporting relationship
- Director
- Issuer ticker
- NVAX
- Reported as of
- 16 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2022, 20:48:52 UTC
- Prior SEC filing
- 20 Dec 2021
- Next SEC filing
- 16 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John A. Herrmann III, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael A. Mcmanus Jr. filed Form 4 for NOVAVAX INC (NVAX) on 21 Jun 2022.
Change
- Previous filing in this sequence was filed on 20 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVAX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +700
- Change %
- +7.4%
- Price
- Shares after
- 10,101
- Date
- 16 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NVAX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -700
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 700
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
Footnote F2
In connection with the reporting person's departure from the Board of Directors (the "Board"), the Board accelerated the vesting of 700 RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), to June 16, 2022 from June 17, 2022.